Autopsy report · NCT02956629

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

“The study was terminated based on review of Phase 2 efficacy data”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 282 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Hepatitis C

Interventions

Uprifosbuvir; Ruzasvir; Ribavirin

Participants

282

Trials that died the same way

• A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
  “This study was terminated due to limited efficacy and not due to safety reasons” (79% match in meaning)
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
  “The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.” (79% match in meaning)
• Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
  “This study was terminated for reasons not related to efficacy or safety” (78% match in meaning)
• A Study of Tadalafil for Duchenne Muscular Dystrophy
  “The study is being terminated for lack of efficacy” (77% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.